神經分泌生物科學 NBIX 深 滬
等待開盤 09-10 09:30:00 美东时间
144.17
+0.370
+0.26%
華盛通- 最 高144.21
- 今 開143.50
- 成交量 56.98万股
- 最 低 141.78
- 昨 收 143.80
- 總市值 142.68亿
- 52周最高 154.61
- 市盈率 靜 43.80
- 換手率 0.58%
- 52周最低 84.23
- 委 比 -77.38%
- 總股本 9896.58万
- 歷史最高 157.9799
- 量 比 0.54
- 振 幅 1.69%
- 歷史最低 5.42
- 每 手 1
- 風險率 12.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views
Providing a diverse range of perspectives from bullish to bearish, 12 analysts ...
09-05 21:01
Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $163
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $158 to $163.
09-05 20:32
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
NANOBIOTIX, a late-clinical stage biotechnology company, announced that its management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The event will take place in New York City at 9:00 am EDT / 3:00 pm CEST. CEO Laurent Levy and CFO Bart van Rhijn will present, with a live webcast available on the Company’s events page, followed by a replay. Nanobiotix, headquartered in Pa...
09-02 20:15
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
Nautilus Biotechnology, Inc. will participate in two investor conferences: Morgan Stanley's Global Healthcare Conference on September 8 and the Q3 Investor Summit Group Virtual Conference on September 16. Access live webcasts on their website at www.nautilus.bio.
08-27 12:00
艾伯维的“第二春”
（来源：药剂Talks） “自免一哥”艾伯维剑指“CNS王座”！ 在艾伯维第二季度财报电话会议上，现任总裁兼首席执行官Robert A. Michael表示...
08-21 18:59
美股大行评级 | 罕见！Meta、微软连续获多家大行上调目标价；花旗上调Robinhood目标价升至120美元
今日重点评级关注：丰业银行：维持Arcellx"跑赢大市"评级，目标价从93美元升至133美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从89美元升至100美元
08-01 10:17
Moderna's Earnings: A Preview
Moderna (NASDAQ:MRNA) is preparing to release its quarterly earnings on Friday,...
07-31 23:02
Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $141
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $137 to $141.
07-31 21:14
Neurocrine Biosciences shares are trading lower following Q2 reported financial results.
Neurocrine Biosciences shares are trading lower following Q2 reported financial...
07-31 04:41
Preview: United Therapeutics's Earnings
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings ...
07-30 00:03
